Sanara MedTech receives FTC Second Request, HSR waiting period extended for MiMedx merger

Sanara MedTech (SMTI) received a Second Request from the FTC, extending the HSR waiting period for its merger with MiMedx. The waiting period will last until 30 days after substantial compliance, unless extended or terminated. The merger's completion is contingent on this waiting period and other closing conditions. Sanara MedTech is cooperating with the FTC.

Original reporting
Published Oct 16, 2026, 1:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sanara MedTech receives FTC Second Request, HSR waiting period extended for MiMedx merger — source image
Decision brief

The 30-second read

$SMTINeutralMed
01

Why it matters

Regulatory review adds uncertainty, possibly delaying the deal and affecting share price volatility.

02

Market read

The FTC's action introduces short‑term risk to the merger, prompting traders to monitor regulatory developments.

03

What to watch

Potential synergies and strategic fit between Sanara and MiMedx may outweigh regulatory timing concerns.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Sanara MedTech (SMTI) announced a pending merger with MiMedx, now facing an FTC Second Request that extends the HSR waiting period.

Company-level read

Ticker impact

$SMTINeutralHigh confidence
Context

FTC issued a Second Request extending the HSR waiting period for Sanara MedTech's pending merger with MiMedx.

Expected impact

likely pressure as the market prices in the extended waiting period and potential further regulatory hurdles

Evidence & confidence

A Second Request is a material regulatory step that can stall or derail a merger, prompting traders to reassess the deal's probability.

Market effects

M&A activity in the med‑tech sector may face heightened regulatory scrutiny.

U.S. biotech and med‑tech stocks could see short‑term volatility.

Limited to companies involved in the specific transaction.

Counterpoint

The merger could still close on schedule if the FTC's request is satisfied quickly, making the delay a temporary blip.

Key entities

  • Sanara MedTech Inc.

    U.S. med‑tech firm pursuing a merger with MiMedx.

  • MiMedx Group Inc.

    Target of the merger with Sanara MedTech.

  • Federal Trade Commission (FTC)

    Issued a Second Request, extending the HSR waiting period.

Related articles

$SMTIMed

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

$MDXGMed

MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36%

MiMedx Group Inc (MDXG) reported a 36% revenue jump in Q3 2026. CFO Danilo D'Alessandro expects gradual reduction in cash burn over the next four to six quarters. CEO Joe Burnett highlighted growth opportunities in spine laser therapy, with estimated revenue of $13,000 to $20,000 per procedure. The company aims for mid-teens growth in 2027, with guidance expected in January. MDXG also discussed investments in robotics and focused ultrasound, and the status of the UniQure AMT-130 BLA submission.

$MDXGMed

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGHighAI 8/10

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.

$MDXGMed

MiMedx: Q3 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q3 loss of $8.7 million, or 6 cents per share, with adjusted losses of 1 cent per share. Revenue was $62.3 million. The company expects full-year revenue between $250 million and $260 million, according to its earnings release.